Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non–small cell lung cancer.
Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with nonsmall cell lung cancer (NCSLC).
The current standard of care for patients with NCSLC is crizotinib (Xalkori), but this treatment does not have a high response rate and does not allow for good control of brain metastases. Entrectinib (RXDX-101) is currently being tested in clinical trials and has proven to have better control on brain metastases.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More